What Oltan D treats: main uses and benefits

Oltan D, which contains olanzapine and fluoxetine, is a combination medication relevant in contexts involving certain distressing symptoms. It is commonly used for managing conditions characterized by periods of heightened symptoms in clinical settings involving acute or unstable symptom patterns.

The comparable combination is considered relevant for managing symptoms linked to acute depressive episodes associated with Bipolar I Disorder in adults and symptoms associated with Treatment-Resistant Depression. The core therapeutic domains are addressed within conditions where symptoms may intensify temporarily, presenting with systemic or localized discomfort. This combination is applied in contexts involving these specific symptom patterns.

This supports the patient during episodes marked by temporary physiological imbalance and is commonly used when supportive symptomatic assistance is appropriate. It contributes to easing the overall symptom load and may assist with maintaining functional stability. The use of this combination is applied in addressing symptom clusters that may become intense or disruptive, contributing to improved day-to-day comfort during symptomatic periods and supports general well-being during symptomatic phases.

---

Quick Fact: May assist with symptoms that interfere with daily functioning

Eligibility Map: Who can and cannot use Oltan D

Oltan D (Olmesartan Medoxomil/Hydrochlorothiazide) is approved for use in adults with essential hypertension not adequately controlled by monotherapy. Official regulatory documents define who cannot use the medicine based on absolute prohibitions and specific patient characteristics.

Classification	Population or Condition
Contraindicated	Patients with Anuria, known Hypersensitivity to the drug or sulfonamide-derived drugs, Severe Renal Impairment, or Severe Hepatic Impairment/Biliary Obstruction.
Contraindicated	Pregnant Women (due to Fetal Toxicity); immediate discontinuation is required upon detection of pregnancy.
Contraindicated	Patients with Diabetes Mellitus taking concomitant Aliskiren (dual RAS blockade).
Restricted Use	Patients with Mild to Moderate Hepatic or Renal Impairment must be monitored closely for function and electrolyte balance.
Conditional Use	Volume- or Salt-Depleted patients should have their condition corrected prior to treatment initiation due to the risk of symptomatic hypotension.
Not Recommended	Pediatric Patients (safety and effectiveness have not been established) and Breastfeeding/Nursing Mothers.

Regulatory documents use these classifications to strictly define the appropriate population, emphasizing that use is not established in children and is prohibited in several conditions, particularly those involving severe organ dysfunction or pregnancy.

Interactions with other medicines and products

This section outlines clinically significant drug interactions documented for Oltan D (Olmesartan Medoxomil) in regulatory labeling, focusing on constraints and necessary precautions.

---

Contraindicated and Restricted Combinations

Interacting Agent	Interaction Rationale
Aliskiren	Contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m^2) due to increased risk of hypotension, hyperkalemia, and renal changes.
Other RAS Inhibitors (ACE Inhibitors, other ARBs)	Not generally recommended due to increased risks associated with dual blockade of the Renin-Angiotensin System.

Pharmacodynamic and Absorption Interactions

Interacting Agent	Interaction Effect and Management
Agents Increasing Serum Potassium (e.g., Potassium-sparing diuretics)	Increased risk of hyperkalemia (elevated potassium levels).
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Potential for attenuated antihypertensive effect and risk of renal function deterioration, particularly in volume-depleted or elderly patients.
Lithium	Increased serum Lithium concentrations and risk of toxicity; requires close monitoring.
Colesevelam Hydrochloride	Reduces the systemic exposure of Oltan D. Requires Oltan D to be administered at least 4 hours prior to Colesevelam.

Oltan D can be taken with or without food, as food does not significantly impact its absorption.

Oltan D functions as a highly selective competitive antagonist targeting the Syk (spleen tyrosine kinase) enzyme primarily within key immune cell populations, including B-cells and mast cells. This specific biological interaction is achieved by Oltan D occupying the ATP-binding cleft of the Syk protein, which sterically inhibits the enzymatic transfer of phosphate groups.

This molecular blockade prevents the initial activation of key downstream signaling molecules. The inhibition specifically disrupts signal transduction propagated through the B-cell receptor (BCR) and FcyR pathways. By stopping this critical intracellular phosphorylation cascade, Oltan D interrupts the necessary signaling required for the activation and degranulation of mast cells and macrophages.

The resulting intracellular process is a reduction in the overall activation state of these immune cell types. This translates to a systemic physiological consequence: a diminished cellular capacity for the sustained production and release of inflammatory cytokines and chemokines, thereby modulating the overall immune response cascade at a fundamental cellular level.

How to Use Oltan D

Oltan D is a prescription-only combination medication that must be used strictly according to the regimen defined in official prescribing information. It is administered for the long-term management of essential hypertension in adult patients whose blood pressure is not adequately controlled by either of the individual components (olmesartan or hydrochlorothiazide) alone.

---

Official Administration and Dosage

Feature	Official Instruction Summary
Route and Form	Oral administration only, as an oral film-coated tablet.
Frequency	Taken once daily.
Timing	May be taken with or without food.
Preparation	The tablet must be swallowed whole with sufficient fluid and should not be chewed.

---

Standard Dosing and Adjustment

Treatment typically involves a starting dose selected based on the patient's existing monotherapy, such as 20 mg olmesartan/12.5 mg HCTZ or 40 mg olmesartan/12.5 mg HCTZ once daily. The dose can be adjusted, if necessary, after an interval of 2 to 4 weeks. The maximum recommended daily dose for the combination is 40 mg olmesartan / 25 mg HCTZ. To maintain consistent drug levels, it is recommended to take the tablet at the same time each day.

---

Population-Specific Use Constraints

Official prescribing documents include specific constraints for vulnerable populations:

• Renal Impairment: The medication is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min).
• Hepatic Impairment: It is contraindicated in patients with severe hepatic impairment, cholestasis, or biliary obstruction.
• Pediatric Population: The medication is not established for use in children and adolescents under 18 years of age.

Recent Clinical Evidence

This section summarizes the published findings from clinical studies and research investigations involving this compound.

Research on Compound's Action

Research has evaluated the hypothesis that the compound acts by selectively blocking the COX-2 enzyme. Studies examined the relationship between the compound and prostaglandins, which are related to pain and inflammation. Research efforts continue to assess this mechanism in the context of observed changes in patient symptoms.

Clinical Trial Outcomes

Acute Pain Management

Studies explored the compound's effect on moderate to severe acute pain, such as post-operative dental pain. Randomized, controlled trials investigated the compound's relationship with pain intensity compared to both placebo and other analgesics. These short-term trials (typically less than 7 days) evaluated various pain scores and the need for rescue medication.

Chronic Inflammatory Conditions

Clinical trials investigated whether the compound was associated with changes in mobility and quality of life in adult patients with rheumatoid arthritis (RA) and osteoarthritis (OA).

Condition	Primary Study Outcome	Comparative Finding
Osteoarthritis (OA)	Measured pain and stiffness scores	Study results indicated a difference compared to placebo over a 12-week period.
Rheumatoid Arthritis (RA)	Joint swelling, tenderness, and function scores	Longer studies monitored changes in patient-reported function over periods up to one year.

️ Safety Profile Studies

Long-term comparative studies explored whether the compound was associated with a different observed incidence of gastrointestinal (GI) side effects compared to non-selective NSAIDs. Studies focused on patients with known cardiovascular risk factors examined the relative incidence of major adverse cardiovascular events (MACE) when compared to placebo or other NSAIDs. Some research examined patient outcomes across a range of doses and treatment periods.

Information available does not replace consultation with a healthcare provider regarding medical decisions or changes to existing treatments.

Common questions about Oltan D (FAQ)

Q: What does the D in Oltan D stand for?

The 'D' in the product name refers to Hydrochlorothiazide (HCTZ). This is the diuretic component of the fixed-dose combination. Official product information confirms that Oltan D contains two active ingredients: Olmesartan Medoxomil and the diuretic Hydrochlorothiazide.

Q: What should I do if I forget to take Oltan D?

Regulatory patient information describes the general guidance regarding a forgotten dose: the information states that a dose may be taken as soon as it is remembered, unless the next scheduled dose is imminent. In that case, the information advises skipping the missed dose and continuing the regular schedule. Regulatory documents state that patients should not take a double dose to make up for a missed one.

Q: Can Oltan D cause changes in appetite or weight?

Based on the documented adverse reactions in regulatory labeling, the medicine is not commonly associated with significant changes in appetite or changes in body weight (gain or loss). The most commonly reported side effects typically involve the central nervous or gastrointestinal systems.

Q: Can Oltan D affect sleep patterns?

Official regulatory documents indicate that sleep disturbances, specifically insomnia (difficulty sleeping), are potential side effects of the medicine. Changes in sleep patterns are generally managed in consultation with a healthcare provider.

Q: What are the most common reasons people stop taking Oltan D?

Data collected during clinical trials show that the most frequent reasons for participants discontinuing the medicine due to side effects were dizziness and headache. Less commonly, nausea or fatigue led to stopping the medication.

Q: Is there any risk associated with driving while taking Oltan D?

The official labeling includes warnings that side effects like dizziness, tiredness, or fainting (syncope) may occur while taking Oltan D. These effects may impact a person's ability to drive or operate machinery.

Q: Can Oltan D cause problems with vision?

Yes, the Hydrochlorothiazide component of the medicine carries a specific warning. Regulatory documents highlight a rare but serious risk for developing acute transient myopia and acute angle-closure glaucoma, which are conditions affecting vision.

Q: Does Oltan D affect fertility?

While regulatory documents strictly prohibit the use of the medicine during the later stages of pregnancy due to fetal risk, they do not contain specific information on the effects of Oltan D on human fertility (the ability to conceive) in either men or women.

Q: Is Oltan D a controlled substance?

Oltan D is classified as a prescription-only medicine. According to regulatory authorities, the medication is not designated as a controlled substance and is therefore not subject to the special restrictions that apply to scheduled drugs.

Q: Is Oltan D used for pain relief?

No. Official documents state that Oltan D is indicated only for the management of essential hypertension (high blood pressure). It is not approved or indicated for the relief or treatment of pain.

Q: How long does Oltan D stay in your system after stopping it?

The time the medicine stays in the body is described by its half-life (pharmacokinetics). Official information indicates that the active components, Olmesartan and Hydrochlorothiazide, have elimination half-lives that range from approximately 5 to 15 hours.

Q: What does official research say about the long-term effects of Oltan D?

Clinical studies supporting the product's regulatory approval primarily focused on evaluating the medicine's effect on blood pressure reduction over time. These trials also documented the side effect profile over treatment periods typically lasting up to one year.

Q: Does taking Oltan D with certain vitamins or supplements cause a problem?

The official labeling provides detailed information on clinically significant interactions with certain prescription medications. However, regulatory documents generally do not contain specific information on interactions with most common over-the-counter vitamins or general dietary supplements.

Q: Does Oltan D make you feel 'foggy' or mentally slow?

Regulatory labeling lists common adverse reactions such as dizziness and headache in some patients. It does not, however, specifically document or list subjective terms like 'mental slowness' or 'brain fog' as frequent or common side effects.

Q: Are there different strengths of Oltan D available?

Yes, Oltan D is supplied in several different strengths. According to dosage and administration information, the fixed-dose combination typically includes Olmesartan at 20 mg or 40 mg combined with Hydrochlorothiazide at 12.5 mg or 25 mg.

Q: How quickly should I expect Oltan D to start working?

Clinical pharmacology data suggests that measurable reductions in blood pressure are usually observable within one week of starting the medication. The full therapeutic effect of lowering blood pressure is typically achieved after approximately four weeks of initiating therapy.

Q: Is Oltan D used to treat anxiety?

No. The official indication for Oltan D is strictly for the management of essential hypertension (high blood pressure). It is not approved or indicated by regulatory bodies for the treatment of anxiety or other mental health conditions.

Q: Does Oltan D have any special considerations for teenagers?

The safety and effectiveness of Oltan D have not been established for use in children and adolescents under the age of 18. Regulatory documents strictly define the approved patient population as adults.

Q: Do most people taking Oltan D experience side effects?

Clinical trial data indicates that common side effects, such as headache or dizziness, occur in a documented percentage of patients. However, overall serious adverse events requiring medical attention are documented as uncommon or rare.

Q: Is Oltan D safe for older adults to use?

The medication has been used in clinical trials involving older adults. Due to the increased likelihood of decreased kidney function in the elderly population, official guidance recommends close monitoring of renal function when Oltan D is administered to these patients.

Q: Why is Oltan D sometimes prescribed with other medicines?

The medicine itself is a combination of two agents, and it is approved for patients whose blood pressure is not controlled by monotherapy (a single agent). When a patient’s blood pressure is still not adequately controlled, combination therapy involving Oltan D and other medicines is a recognized strategy in blood pressure management.

Q: Is Oltan D a generic version available?

According to regulatory drug status information, generic versions of the active components, Olmesartan Medoxomil and Hydrochlorothiazide, are available.

Oltan D must be stored according to strict regulatory guidelines to maintain its stability and effectiveness.

Official Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C), with temporary excursions permitted up to 30 C.
Protection	Keep the tablets from freezing and protect them away from light, moisture, and excess heat.
Packaging	Keep the medicine in its original container and ensure the container is tightly closed.

Handling and Disposal

It is mandatory to keep Oltan D out of the reach of children. Regarding disposal, do not keep outdated or unneeded medicine. Users are instructed to consult a healthcare professional for guidance on the proper way to discard any unused product.